Questions Swirl Around US Aflibercept With Biocon Decision Imminent
West Virginia Court Decision Comes Ahead Of Key May 2024 Reg. Exclusivity End
Executive Summary
Biocon’s ongoing legal battle with Regeneron over US patents shielding Eylea was discussed by the originator at a pair of recent healthcare conferences, with a decision due any day.
You may also be interested in...
Formycon Gets Date For Aflibercept Filing In US
Formycon has announced a June 2024 FDA action date for its FYB203 proposed aflibercept biosimilar rival to Eylea, which is due to be marketed by Coherus in the US.
Sandoz Puts Aflibercept In Its Sights With Phase III Data
Sandoz is looking to move ahead with its planned filings for one of the most significant off-patent biologic opportunities in the coming years – Eylea (aflibercept).
Viatris Believes Eylea Biosimilar Candidate Is First To Reach US FDA’s Desk
Viatris provided several key updates for its biosimilar pipeline during the company’s Q3 earnings call, including for its biosimilar Eylea and Botox candidates, as well as disclosing another key early-stage asset.